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December 20101746 Abstractstransmitral flow velocity (E), the atrial transmitral flow velocity (A), and the
mitral annular tissue doppler velocity (e=). Patients were divided into two
groups of diastolic dysfunction as either none/mild (E/A  0.75, E/e= 
10) or moderate/severe (E/A  0.75, E/e=  10). Perioperative and
long-term mortality was determined from a prospective vascular database
and the National Death Index. Descriptive statistics were calculated. Post-
operative survival was estimated by product-limit methods. Associations
between preoperative and perioperative factors and long-term survival were
examined using proportional hazards regression models. A backwards vari-
able elimination procedure was used to select a ‘best’ model to predict
long-term survival.
Results: Seventy-six patients were followed for an average of 41.9
months after renal revascularization. Within this group, 47/76 (61.8%)
patients were identified as having moderate or severe diastolic dysfunction.
Systolic function was preserved. The mean ejection fraction for the entire
group was 58.3%  11.1%. Diastolic dysfunction had no apparent associa-
tion with abnormal systolic function. The mean ejection fraction for those
with moderate/severe diastolic dysfunction was 57.7%  11.5%. When
comparing the moderate/severe and none/mild groupings of diastolic
dysfunction, there was a significant difference in left ventricular mass index
(151.9  48.9 vs 125.3  31.7, P  .0087). There were five deaths in the
perioperative period and 20 deaths on follow-up. Among survivors, hyper-
tension was cured or improved in 82% of the none/mild group and 53% of
the moderate/severe group (P  .012). Renal function was improved in
32% of the none/mild group and 26% of the moderate/severe group (P 
.54).Multivariate analysis among 71 perioperative survivors demonstrated a
significant and independent association between diastolic dysfunction and
survival (HR 5.1, 95% CI 1.1-23.6, P .037) (Fig 1). Ejection fraction did
not have a significant effect on long-term survival. Backward elimination
resulted in a final model that included diastolic dysfunction (HR 5.8, 95%CI
1.4-25, P .018) and history of stroke/TIA (HR 2.5, 95% CI 0.9-7.1, P
.092) as the only signficant predictors of long-term survival.
Conclusions: Diastolic dysfunction, but not systolic function, was
frequent in patients with renovascular disease. After renal revascularization,
diastolic function had a significant and independent association with long-
term survival. Preoperative assessment of diastolic function should be con-
sidered in patients prior to surgical repair.
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Background: Vertebral arterial disease (VAD) is a less commonly
recognized and treated source of cerebro-vascular ischemia compared to
carotid artery disease. Patients are often referred for treatment after they
have developed symptoms in the form of TIA or have had a posterior
hemispheric stroke. Traditional treatment of VAD has been surgical. More
recently, endovascular treatment of VAD has been utilized.
Methods: We performed a retrospective review of our institutional
experience in treating proximal VAD from 2001 to 2010. After obtaining
IRB approval, 53 patients were identified for review. Hospital and office
record data from the Division of Vascular Surgery and the Department of
Radiology was reviewed.
Results: Thirty-six patients had surgery and seventeen patients had
endovascular therapy. All patients in the surgical arm were symptomatic.
Symptoms included: ataxia (56%), dizziness (19%), syncope (11%), visual
symptoms (13.8%), and major stroke (8.3%) Fifteen of the patients in the
endovascular arm were symptomatic. Symptoms included: major stroke
(40%), visual symptoms (13.3%), dizziness (13.3%), ataxia (6.7%), and
syncope (6.7%). Demographics of the surgical and endovascular patients
were similar for: age (68.3 vs 62.2 years), CAD (58% vs 65%), HTN (78% vs
76%), DM (41% vs 53%), and history of tobacco use (75% vs 70%). Incidence
of major stroke prior to treatment was lower in the surgical group (8.3% vs
40%). In the surgical group: average length of stay was 2.1 days. There weremajor complications in two patients (5.6%). Complications included: bleed-
ing requiring re-intubation and surgical evacuation, and myocardial infarc-
tion (which caused the one death [2.8%]). Symptoms were relieved com-
pletely in 86%, partially in 5.6% and not at all in 8.3% of patients. In the
endovascular group, average length of stay was 5.8 days. There were no
major periprocedural complications, however, 6-week mortality was 11.7%.
Symptoms resolved completely in 27%, partially in 63%, and not at all in 9%
of symptomatic patients.
Conclusions: For treatment of proximal VAD, perioperativemorbidity
was lower for the endovascular group than the surgical group, but the
6-week mortality was higher for this treatment modality. Complete resolu-
tion of symptoms occurred more frequently with surgery than with endo-
vascular therapy (86% vs 27%). Therefore, in general, surgical reconstruction
appears to be preferable to angioplasty and stenting for the treatment of
proximal vertebral artery occlusive disease.
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Background: Acute surgical conversion during endovascular aortic
aneurysm repair (EVAR) is uncommon. Outcomes and predictors of intra-
operative conversion are unknown. This report examines EVAR conversions
using the American College of Surgeons National Surgical Quality Improve-
ment Program Database for years 2005-2008.
Methods: Conversion cases occurring during elective EVAR were
identified using CPT codes. Nonemergent EVAR and primary open surgical
repairs of infrarenal aneurysms were also examined for comparison. Periop-
erative morbidity was categorized as: wound, pulmonary, venous thrombo-
embolic, genitourinary, cardiovascular, operative, and septic. Mortality,
overall morbidity, and length of stay (LOS) were also examined. Differences
among repair groups for descriptive and outcome variables were evaluated
using 2 tests, and linear or logistic regressions. Predictors of conversion
were also evaluated using logistic regression.
Results: Seventy-two conversions, 2414 open repairs, and 6332
EVARs were identified. Demographics and comorbidities were generally
similar among operative groups. Mean operative time for conversion cases
was 274 113 minutes compared to 226 93 minutes for open repair and
162  74 minutes for EVAR cases (conversion vs EVAR and open repair vs
EVAR (P  .0001 for each], and conversion vs open repair P  .0014;
analysis on rank operative time). Sixty-nine percent of patients undergoing
conversion required red blood cell transfusion with a mean volume of 6.0
6.3 units vs 73% of open repairs (mean volume 3.3 3.3 units), and 12% of
EVAR (mean volume of 2.6  2.5 units) (P  .0001 for each pair-wise
comparison; analysis on rank number of units among those transfused).
Major morbidity occurred in 28% of conversions, 28% of open repairs, and
12% of EVARs. Mortality was 4.2% for conversions, 3.2% for open repairs,
and 1.3% for EVARs.Median (Q1,Q3) LOSwas 7 (5, 9) days for conversion
and open repair, and 2 (1, 3) days for EVAR. Morbidity and mortality were
significantly higher for conversion and open repair vs EVAR (OR [95%CI]
for morbidity 2.9 [1.7, 4.8] and 2.8 [2.5, 3.2], for conversion and open
repair, respectively [P  .0001 for both]: OR [95% CI] for mortality 3.4
[1.0, 10.9] P .0437 and 2.5 [1.9, 3.5] P .0001, for conversion and open
repair, respectively). Morbidity and mortality were similar between conver-
sion and open repair (OR [95% CI] 1.0 [0.6, 1.7] P  .9780 and 1.3 [0.4,
4.3] P  .6445 for morbidity and mortality, respectively). A similar pattern
among repair groups was demonstrated for log-LOS, with similar LOS for
conversions and open repair which were significantly longer than that
observed for EVAR. No significant demographic or medical risk factor
predictors of conversion were identified.
Conclusions: Conversion was a rare complication affecting 1.1% of
EVAR cases with no broadly identifiable at-risk population. When conver-
sion did occur, morbidity andmortality paralleled those observed for elective
open repair.
A Single Center Experience Comparing Tibial Bypass with Heparin-
Bonded ePTFE vs Saphenous Vein
Richard F. Neville, Avery Capone, Richard Amdur, GeorgetownUniversity,
Washington, DC
Background: Several series have reported that heparin bonded PTFE
(HePTFE) grafts perform in an equivalent manner to saphenous vein (SVG)
for tibial bypass. This series reports a single center, US experience for tibial
bypass using the HePTFE and SVG over a contemporaneous time period.
Methods: A retrospective analysis of prospectively collected data was
conducted for 112 tibial bypasses performed from November 2006 to
January 2009 including 62 HePTFE and 50 SVG. Patient demographics
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race (44% white, 54% AA), DM (57%), and ESRD (15%). Indications for
revascularization were similar; claudication 9%, rest pain 25%, and tissue loss
66%. The HePTFE group included more re-operative procedures (45% vs
26%). Postoperative graft surveillance by pulse exam, ABI, and Duplex
ultrasound was at 1, 3, 6, and 12months. The follow-up period ranged from
1 to 12 months with Kaplan-Meier and Cox regression analysis used to
evaluate results in those patients with all variables non-missing.
Results: HePTFE and SVG bypasses demonstrated no difference in
target artery; AT (15 vs 17), DP (4 vs 5), PT (22 vs 16), and peroneal (21 vs
12). Venous conduit was absent in the HePTFE group due to prior bypass
(32%), CABG (29%), stripping (12%), or poor quality vein (27%). Nineteen
patients (18.6%) suffered graft occlusion or death during follow-up. There
was no significant difference in primary patency due to gender (male 78% vs
female 84%), race (white 82%, AA 77%), or diabetes (non-DM 84%, DM
76%). ESRD resulted in decreased patency (57%) with an eightfold reduc-tion (95% CI 1.8-39.8). Patency was highest for claudicants (95%) with rest
pain (81%), gangrene (71%), and ulcer (72%) decreased, respectively. Pri-
mary patency based on conduit was HePTFE 75% and SVG patency 86%.
SVG patients had a 78% lower risk of occlusion/death (P  .05, 95% CI
14.2-94.5%). Thirty-seven patients had a secondary procedure (33%); HeP-
TFE 23, SVG 14. Significant factors related to a second procedure included
age and ESRD. There were 16 amputations (14%) with a mean time to
amputation of 4.9 months. There was no difference based on conduit;
HePTFE 9, SVG 7.
Conclusion: This is a single center contemporaneous experience with
HePTFE and vein for tibial bypass. Three factors were related to decreased
1 year patency; ESRD, non-healing ulcer, and type of conduit. There was no
difference in limb salvage based on the bypass conduit employed. This initial
experience demonstrates the superiority of a quality saphenous vein as a
conduit for tibial bypass, but HePTFE may represent an alternative with
multicenter data required to further define its role for tibial bypass.
